Selective Bruton’s Tyrosine Kinase Inhibitor in Waldenström Macroglobulinaemia1
Bruton’s tyrosine kinase inhibitors (BTKi) have established promising therapeutic benefit in patients with Waldenström Macroglobulinaemia (WM). Zanubrutinib, a novel selective BTKi, has been investigated and its efficacy and safety profile have been reported recently. The clinical trial included patients with WM who were either treatment-naïve or had relapsed/refractory disease. With a median follow-up of 3 years, the overall response rate was 96% and the very good partial response/complete response was 45%. Approximately 80% of patients were estimated to survive without disease progression at 3 years. However, it is inconclusive whether zanubrutinib is superior to the existing treatment options of WM.
References
1. Trotman J, et al. Blood. 2020; 136: 2027-2037.
